role in cardiac development and the Hippo pathway regulation. This pathway is essential for heart development and repair. By targeting this pathway, Prolifagen seeks to offer new solutions for myocardial infarction treatment, prevent heart remodeling, and promote tissue regeneration. The company is a preclinical spin-out of the University of Pennsylvania, indicating its strong research foundation and commitment to translating scientific discoveries into potential medical breakthroughs.